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Purpose of the study
Hypophosphatemia (HP) and renal dysfunction have
been associated with antiretroviral therapy, especially
with the use of tenofovir disopropil fumarate (TDF).
Thus, recent guidelines recommend routine phosphate
measurements in HIV-infected patients. We aimed to
assess the utility of this monitoring.
Methods
Retrospective cohort study of 680 patients with renal
monitoring on antiretroviral therapy from 2008 to 2010.
The frequency of HP was compared in TDF recipients
with that in non-TDF recipients, as well as assessed the
reproducibility of HP, and identified the incidence of
renal dysfunction in hypophosphatemic patients
Results
Phosphate measurements were obtained in 265 patients
during follow-up. Mean age was 40.66 (±7.68) years,
76.2% were men, 47.9% were IDU, and 84.9 % received
an antiretroviral regimen based on TDF. At baseline,
before antiretroviral therapy, hypophosphatemia was
observed in 4 of 67 patients (6%). Overall, during follow
up, HP was observed in 56 of 265 (21.1%), but was con-
firmed only in 33 (12.5%). The median time to HP was
798(±13.95) days, usually with phosphate levels above 2
mg/dl (mild HP). A higher percent of patients pre-
scribed TDF showed a phosphate measurement below
normal limits (13.8%) in comparison with those patients
receiving non-TDF based therapy (5%), although this
comparison was not significant (p=0.103). There was no
difference with regard to time to HP in patients
receiving TDF or not (median time 798 vs 834 days,
p=0.106 log-rank test), neither in the values of serum
creatinine or MDRD in patients with or without
hypophosphatemia.
Conclusions
HP is relatively frequent in HIV infected patients on
antiretroviral therapy, although we did not find any
clear association with any specific therapy or renal dys-
function as measured by serum creatinine or glomerular
filtration. This fact questions the utility of routine phos-
phate testing, in isolation, in TDF recipients.
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